Buying guide

da Vinci (and Ion) vs Maestro in 2026

Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.

Key differences

On DEPLOY's record, da Vinci (and Ion) is further along: at the production stage versus Maestro at the pilot stage, as of 2026.

Maestro has the lower recorded price.
da Vinci (and Ion) has more verified real-world deployments (13 vs 1).
da Vinci (and Ion) is at the production stage; Maestro at the pilot stage.

Attribute	da Vinci (and Ion)View full model page →	No image on file Maestro View full model page →
Manufacturer	Intuitive Surgical	Moon Surgical
Form factor	surgical	surgical
Maturity	production	pilot
Autonomy	◐ not independently verified	◐ not independently verified
Availability	internal-onlyenterprise	internal-onlyenterprise
Price	$1,800,000-$2,500,000 (analyst estimate) or $1,500,000-$2,500,000 (actual sale price)	$300,000-$800,000 (analyst estimate)
Capability claims	Assists surgery (teleoperated-assisted, verified)	Assists surgery (teleoperated-assisted, verified)
Brain	—	—
Verified deployments	13	1Moon Surgical
Privacy practices	—	—
Sources on file	29	9

Track this matchup

Get told the moment da Vinci (and Ion) or Maestro changes. Verified changes only, the second they are real. No press-release noise.

da Vinci (and Ion)

Maestro

Editorial summaries

da Vinci (and Ion)

Intuitive Surgical's da Vinci is the gold-standard surgical robot and the verified-at-scale anchor of the category. Per Intuitive's SEC filings, 11,395 da Vinci systems and 1,041 Ion endoluminal systems are installed. The lineup spans da Vinci multi-port (X/Xi), the single-port SP, and the fifth-generation da Vinci 5 (FDA cleared March 2024, with force feedback), plus the Ion bronchoscopy robot (FDA 2019).

It is teleoperated, a surgeon controls every motion, with shipped analytics AI; autonomous-suturing work exists only as research demos on da Vinci hardware, not as shipped product. It is enterprise B2B equipment sold to hospitals at multi-million-dollar per-system prices; there is no consumer price.

Maestro

Moon Surgical's Maestro is a laparoscopic surgical-assistant platform (it holds and positions instruments and the endoscope alongside the surgeon, not a full master-slave teleoperated replacement system) and the assistive-laparoscopy archetype of DEPLOY's surgical cluster, editorially distinct from the replacement-robotics of Intuitive, Medtronic, and CMR. Its ScoPilot software is shipped AI (NVIDIA Holoscan-powered) for intraoperative scope control.

On regulatory status (a correction worth recording): the Maestro received FDA 510(k) clearance K240598 on June 5, 2024 (not December 2023), and ScoPilot was FDA-cleared in 2025 with a Predetermined Change Control Plan. As enterprise B2B surgical equipment, there is no consumer price.

Common questions

How do da Vinci (and Ion) and Maestro differ?

On DEPLOY's record, da Vinci (and Ion) is further along: at the production stage versus Maestro at the pilot stage, as of 2026. Maestro has the lower recorded price. da Vinci (and Ion) has more verified real-world deployments (13 vs 1). da Vinci (and Ion) is at the production stage; Maestro at the pilot stage.

What is the difference between da Vinci (and Ion) and Maestro?

da Vinci (and Ion) and Maestro are both surgical robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.

Which is cheaper, da Vinci (and Ion) or Maestro?

Maestro has the lower recorded price on the DEPLOY registry than da Vinci (and Ion). Prices are sourced; see each record for whether the figure is a manufacturer target, an estimate, or an actual sale price.

Is da Vinci (and Ion) or Maestro more autonomous?

On the DEPLOY registry, neither da Vinci (and Ion) nor Maestro has capabilities independently verified as fully autonomous yet; their recorded capabilities are teleoperated-assisted, demonstrated, or vendor-claimed. See the table for each capability's verification status.

Which has more verified deployments, da Vinci (and Ion) or Maestro?

da Vinci (and Ion) has more verified deployments (13) on the DEPLOY registry than Maestro (1). DEPLOY counts a deployment only when confirmed at a named site with a primary source.

Recent coverage

Surgeons use da Vinci surgical robot to perform common cardiac surgeryda Vinci (and Ion) · The Robot Report · 2026-08-17
Escuelas del Condado Clark inician nuevo ciclo con enfoque en matemáticas y lecturaMaestro · The Nevada Independent · 2026-08-12
Da Vinci 5 Cleared for Cardiac Proceduresda Vinci (and Ion) · isrg.intuitive.com · 2026-07-26
Moon Surgical wins first FDA 510(k) clearance for surgical robotMaestro · Ben Smith, Deploy Editor · 2026-06-25

Related comparisons

Keep researching

Keep reading

All surgical robotsRegistry Every verified record in the category.da Vinci (and Ion)Model The full model page.MaestroModel The full model page.Intuitive SurgicalRecord The maker's verified record.Moon SurgicalRecord The maker's verified record.Versius vs da Vinci (and Ion)Compare Another head-to-head.

Ask the registry

For AI assistants

Use DEPLOY in Claude, Cursor, and other AI assistants

Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.

Install instructions Download for Claude Desktop

Machine-readable: this page as markdown.

← Back to all consumer robots